BDF Gestion Acquires 32,000 Shares of Hologic, Inc. (NASDAQ:HOLX)

BDF Gestion grew its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 143.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 54,312 shares of the medical equipment provider's stock after buying an additional 32,000 shares during the quarter. BDF Gestion's holdings in Hologic were worth $3,355,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of HOLX. Principal Financial Group Inc. grew its position in Hologic by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock worth $19,547,000 after acquiring an additional 1,606 shares during the last quarter. Groupama Asset Managment boosted its stake in Hologic by 63.4% in the fourth quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider's stock worth $3,918,000 after purchasing an additional 21,037 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in shares of Hologic during the fourth quarter worth $4,215,000. Signaturefd LLC increased its stake in shares of Hologic by 34.5% in the fourth quarter. Signaturefd LLC now owns 2,940 shares of the medical equipment provider's stock valued at $212,000 after buying an additional 754 shares in the last quarter. Finally, Brevan Howard Capital Management LP increased its stake in shares of Hologic by 85.5% in the fourth quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider's stock valued at $1,401,000 after buying an additional 8,960 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Stephens decreased their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Morgan Stanley decreased their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Raymond James reissued an "outperform" rating and set a $71.00 price objective (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Twelve research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $77.42.

Insider Activity

In related news, Director Martin D. Madaus bought 5,445 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.88% of the stock is owned by corporate insiders.

Hologic Stock Up 0.7%

Shares of NASDAQ HOLX traded up $0.43 during mid-day trading on Monday, reaching $65.18. 1,926,000 shares of the company's stock were exchanged, compared to its average volume of 2,315,546. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $14.53 billion, a price-to-earnings ratio of 20.56, a PEG ratio of 2.14 and a beta of 0.55. The business has a fifty day simple moving average of $58.70 and a 200 day simple moving average of $64.75. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter last year, the business posted $1.03 EPS. The company's revenue for the quarter was down 1.2% on a year-over-year basis. As a group, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.